The compound and method of thymoquinone and nystatin for the treatment of oral candidiasis
Patent Information
- Application Number
- PCT/TR2023/050464
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-28
Smart Images

Figure TR2023050464_28112024_PF_FP_ABST
Abstract
Description
[0001] THE COMPOUND AND METHOD OF THYMOQUINONE AND NYSTATIN FOR THE TREATMENT OF ORAL CANDIDIASIS
[0002] TECHNICAL FIELD
[0003] The invention relates to a herbal medicine for the treatment of fungus (candidiasis) in the oral cavity, in which thymoquinone and nystatin are mixed in certain ratios, and to a method of preparation thereof.
[0004] STATE OF THE ART
[0005] Oral candidiasis is the most common well-known fundal infection of the oral mucosa. Candida can grow on normal oral, intestinal and vaginal mucosa without showing any signs of disease. Under suitable conditions, such as weakened resistance or immunity, these microorganisms can cause disease states ranging from a non-serious but unpleasant superficial infection to a fatal systemic infection that spreads through the bloodstream.
[0006] More than thirty species of Candida have been reported. Eight of these are known as human pathogens. Oral thrush most commonly seen in infants and young children causes white lesions on the inner cheeks and tongue. These lesions, which disappear with treatment, are typically mild but can rarely lead to complications. People with weak immune systems can also be affected.
[0007] In the state of the art, the topical fungicides available on the market are nystatin, amphotericin B, miconazole and clotrimazole. However, the effects of these drugs on persistent fungal strains may be insufficient or may be achieved with high doses. The use of high doses of these drugs also brings the risk of toxicity. There is a need in the art for more natural therapeutics with less toxicity risk than the drugs on the market.
[0008] Thymoquinone (2-isopropyl-5-methylbenzo-l, 4-quinone) is the most abundant of the essential oils in black cumin and the most bioactive compound mainly responsible for the biological effects of black cumin. Thymoquinone (TQ) is a hydrophobic compound, which is highly transported in our blood by binding to proteins.
[0009] It scavenges harmful reactive oxygen radicals formed as a result of oxidative metabolism in our cells. Thus, it prevents them from destroying the structure of our cells. Its antiinflammatory effect is based on lipooxygenase and cyclooxygenase enzyme inhibition, which play an important role in the emergence of inflammation. It strengthens the immune system.
[0010] Thymoquinone has several health benefits due to its antioxidant, anti-inflammatory and anticancer properties. It has been shown to reduce inflammation in the body by blocking certain inflammatory enzymes. It also acts as an antioxidant that protects the body from damage caused by free radicals. Thymoquinone has been shown to have anticancer properties in laboratory studies, particularly in relation to breast, colon and pancreatic cancers.
[0011] In the document numbered "EP18745504.3" the invention relates to a composition for the treatment of Candida infections. In other words, it relates to compositions for topical use comprising miconazole or a salt thereof and domifen bromide as active ingredients for use in treating or preventing a fungal infection.
[0012] In particular, the invention numbered “TR2020 / 00422” relates to the synthesis of plastoquinone derivatives 5-(2-isopropylphenylamino)-2,3-dimethyl-l,4-benzoquinone (Cl) and 2,3-dimethyl-5-(2-(trifluoromethyl)phenylamino)-l,4-benzoquinone (C2) for use as an antifungal agent against the fungus Candida albicans, together with preparations containing these compounds and their antifungal / biological agent and other commercial uses.
[0013] Although the present inventions have produced a formulation against candica albicans fungus, they do not meet the requirements of being a more natural formulation than existing drugs and the excess of toxic substances entering the body. Furthermore, the active ingredients used are different from our invention. As a result, the need to overcome the shortcomings and disadvantages of the embodiments and practices the current state of the art and in use today necessitates a development in the relevant technical field.
[0014] DESCRIPTION OF INVENTION
[0015] The present invention relates to a composition of thymoquinone and nystatin and method of use thereof for the treatment of oral candidiasis, which has been developed to overcome the aforementioned disadvantages and bring new advantages to the art.
[0016] The aim of the invention is to produce a drug in which the active ingredient 'thymoquinone', which is of plant origin and used in the treatment of many different diseases in the art of health, is effective in persistent fungal strains even in small doses when mixed with nystatin in certain ratios.
[0017] Another aim of the invention is to create a natural treatment method without any toxic effect thanks to Thymoquinone, which is of plant origin.
[0018] Drawings
[0019] The embodiments of the present invention, briefly summarized above and discussed in more detail below, may be understood by reference to the exemplary embodiments of the invention described in the accompanying drawings. It should be noted, however, that the accompanying drawings only describe typical embodiments of the present invention and shall not be deemed to limit its scope, as the invention may, therefore, permit other equally effective embodiments.
[0020] To facilitate understanding, identical reference numbers have been used where possible to indicate identical elements in the figures. The figures are not drawn to scale and can be simplified for clarity. It is considered that elements and features of one embodiment can be usefully incorporated into other embodiments without the need for further explanation.
[0021] Figure 1: Dose-effect plot for thymoquinone in pg / ml.
[0022] Figure 2: Dose-effect plot for Nystatin in pg / ml. Figure 3: Dose-effect plot for Thymoquinone + Nystatin in pg / ml.
[0023] Explanation of Details in Drawings
[0024] The equivalents of the reference numbers shown in the figures are given below.
[0025] 1- C. albicans ATCC 10231
[0026] 2- C. tropicalis ATCC 750
[0027] 3- C. krusei ATCC 6258
[0028] 4- C. glabrata ATCC 2001
[0029] DETAILED DESCRIPTION OF THE INVENTION
[0030] In this detailed description, preferred alternatives to the composition of thymoquinone and nystatin and method of use for the treatment of oral candidiasis of the invention are described solely for the purpose of a better understanding of the subject matter and in a non-limiting manner.
[0031] The invention relates to a drug formulation for the treatment of fungus containing 50% nystatin and 50% thymoquinone.
[0032] In the invention;
[0033] 1- Antifungal activity of thymoquinone (2-isopropyl-5-methyl-l,4-benzoquinone) (Sigma) was tested on the strains of Candida albicans American Type Culture Collection (ATCC) 10,231 (1), Candida tropicalis ATCC 750 (2), Candida krusei ATCC 6258 (3) and Candida glabrata ATCC 2001 (4).
[0034] The microdilution method was performed using a microwell plate in accordance with Clinical Laboratory Standards Institute (CLSI) standards. The final concentration of Thymoquinone was diluted with Brain Heart Infusion Broth (BHI).
[0035] 2- Antifungal activity of Nystatin (Sigma) was tested on the strains of Candida albicans American Type Culture Collection (ATCC) 10,231 (1), Candida tropicalis ATCC 750 (2), Candida krusei ATCC 6258 (3) and Candida glabrata ATCC 2001 (4).
[0036] The microdilution method was performed using a microwell plate in accordance with Clinical Laboratory Standards Institute (CLSI) standards. The final concentration of Nystatin was diluted with Brain Heart Infusion Broth (BHI).
[0037] 3- Thymoquinone and Nystatin were mixed in equal proportions and antifungal activity thereof was tested on the strains of Candida albicans American Type Culture Collection (ATCC) 10,231 (1), Candida tropicalis ATCC 750 (2), Candida krusei ATCC 6258 (3) and Candida glabrata ATCC 2001 (4)
[0038] Candida albicans, Candida tropicalis, Candida krusei, Candida glabrata strains are highly persistent strains observed in oral candidiasis. Both nystatin and thymoquinone were evaluated individually on these strains and the antifungal efficacy of both agents was tested. As a 3rd experiment, these two agents were combined in equal proportions and their antifungal efficacy was examined. As a result, it was observed that the antifungal therapeutic properties of the two agents in combination were much higher than when both agents were evaluated separately.
[0039] The combination interaction of thymoquinone (TQ) and nystatin was evaluated in Brain Heart Infusion Broth (BHI) for Candida albicans ATCC 10,231 (1), C. tropicalis ATCC 750 (2), C. krusei ATCC 6258 (3) and C. glabrata ATCC 2001 (4).
[0040] The final concentrations of TQ and nystatin combination in BHI were 30 pg / mL, 15 pg / mL, 7.5 pg / mL, 3.75 pg / mL, 1.875 pg / mL, 0.938 pg / mL, 0.469 pg / mL and 0.234 pg / mL. C. albicans ATCC 10,231 (1), C. tropicalis ATCC 750 (2), C. krusei ATCC 6258 (3) and C. glabrata ATCC 2001 (4) strains were diluted according to a 0.5 McFarland turbidity standard and 10 pL was added to each well and incubated overnight at 37 °C. Fungal growth in each well was measured at 600 nm using an Epoch spectrophotometer (Biotek, Germany) according to the manufacturer's instructions. The values of thymoquinone, nystatin and Candida strains in the control wells and the values obtained from the combinations of TQ and nystatin were used to determine the fractional inhibitory concentration (FIC). These FIC values and the value of the FIC index were calculated according to the following formulas:
[0041] FIC of antibacterial A (TQ)= MIC of antibacterial A in combination / MIC of antibacterial A alone,
[0042] FIC of Antibacterial B (Nystatin)= MIC of antibacterial B in combination / MIC of antibacterial B alone.
[0043] FIC of Antibacterial A + FIC of Antibacterial B=^FIC index.
[0044] According to the American Society for Microbiology, the value of the FIC index is then used to determine whether there is synergism, indifference or antagonism between antimicrobial agents and is used to interpret the nature of interactions: synergism<0.5, indifference>0.5 to <4, antagonism>4
[0045] All analyses were performed in SPSS software (IBM SPSS Statistics 25). Statistical significance was set at p<0.05. As a first step in data analysis, normality assumption was checked with Shapiro Wilk test.
[0046] Kruskal-Wallis test was used to examine the difference between the means of variables that did not show normal distribution and had more than two independent groups. Bonferroni test was applied to determine the group or groups that caused the difference.
[0047] Evaluation between TO doses and Candida strains
[0048] When the antifungal effect of TQ was examined in vitro, the minimum inhibitory concentration (MIC) values for C. albicans, C. tropicalis and C. krusei were 15 pg / mL, while 30 pg / mL was found for C. glabrata. A statistically significant difference was observed between the mean ranks of Candida strains and TQ doses (p<0.05). According to the results of the experiments, it was observed that thymoquinone concentrations of 7.5 pg / mL and above significantly suppressed the growth of C. albicans compared to the lower concentrations tested. It was also observed that thymoquinone concentrations of 15 pg / mL and above significantly suppressed C. tropicalis and C. krusei growth, while a minimum of 30 pg / mL thymoquinone was required to inhibit C. glabrata growth (Table 1). In addition, dose-effect plots for thymoquinone are shown in Figure 1.
[0049] Table 1: Comparison of TQ doses and Candida species Dose _ Mean
[0050] Species Min Max X SS p
[0051] (pg / mL) ranks
[0052] C.albicans 30 1.00 1.00 1.0000 .00000 16.50 18.529 .005*
[0053] ATCC 15 1.00 1.00 1.0000 .00000 16.50
[0054] 10231 (1)
[0055] 7.5 .86 1.02 .9621 .08962 18.00
[0056] 3.75 .27 .29 .2774 .01050 5.00
[0057] 1.875 .30 .36 .3333 .03184 10.33
[0058] 0.938 .29 .33 .3154 .02019 8.67
[0059] 0.469 .19 .23 .2136 .02279 2.00
[0060] C.tropicalis 30 1.00 1.00 1.0000 .00000 18.50 19.837 .003*
[0061] ATCC 15 1.00 1.00 1.0000 .00000 18.50
[0062] 750(2)
[0063] 7.5 .91 .94 .9263 .01535 14.00
[0064] 3.75 .57 .60 .5930 .01570 11.00
[0065] 1.875 .53 .53 .5298 .00299 8.00
[0066] 0.938 .00 .00 .0000 .00000 3.50
[0067] 0.469 .00 .00 .0000 .00000 3.50
[0068] C.krusei 30 1.00 1.00 1.0000 .00000 18.50 19.837 .003*
[0069] ATCC 6258 15 1.00 1.00 1.0000 .00000 18.50
[0070] (3)
[0071] 7.5 .92 .93 .9263 .00458 14.00
[0072] 3.75 .57 .61 .5930 .02248 11.00
[0073] 1.875 .52 .54 .5298 .00734 8.00
[0074] 0.938 .00 .00 .0000 .00000 3.50
[0075] 0.469 .00 .00 .0000 .00000 3.50
[0076] C.glabrata 30 1.00 1.00 1.0000 .00000 20.00 15.417 .017*
[0077] ATCC 2001 15 .78 .80 .7910 .00934 17.00
[0078] (4)
[0079] 7.5 .26 .28 .2711 .01290 12.67
[0080] 3.75 .22 .29 .2512 .03365 8.67 1.875 .23 .24 .2338 .00692 4.67
[0081] 0.938 .23 .25 .2413 .01160 7.00
[0082] 0.469 .20 .26 .2338 .03050 7.00
[0083] *p<0.05
[0084] Evaluation between nystatin doses and Candida strains The MIC value for nystatin was 1.875 pg / mL for C. albicans, C. tropicalis and C. krusei and 7.5 pg / mL for C. glabrata. A statistically significant difference was observed between the mean ranks of Candida strains and nystatin doses (p<0.05). It was also observed that nystatin concentrations of 1.875 pg / mL and above were statistically significant in suppressing C. albicans, C. tropicalis and C. krusei, while concentrations of 7.5 pg / mL and above significantly suppressed C. glabrata growth (Table 2). In addition, dose-effect plots for nystatin are shown in Figure 2.
[0085] Table 2: Comparison of nystatin doses and Candida species
[0086] Dose Mean
[0087] Species Min Mak x SS ¥“ p
[0088] (pg / mL) ranks
[0089] C.albicans 30 1.00 1.00 1.0000 .00000 14.00 19.347 .004*
[0090] ATCC 15 1.00 1.00 1.0000 .00000 14.00
[0091] 10231 (1)
[0092] 7.5 1.00 1.00 1.0000 .00000 14.00
[0093] 3.75 1.00 1.00 1.0000 .00000 14.00
[0094] 1.875 1.00 1.00 1.0000 .00000 14.00
[0095] 0.938 .71 .74 .7254 .01637 3.00
[0096] 0.469 .73 .74 .7346 .00447 4.00
[0097] C.tropicalis 30 1.00 1.00 1.0000 .00000 14.00 19.837 .003*
[0098] ATCC 15 1.00 1.00 1.0000 .00000 14.00
[0099] 750(2)
[0100] 7.5 1.00 1.00 1.0000 .00000 14.00
[0101] 3.75 1.00 1.00 1.0000 .00000 14.00
[0102] 1.875 1.00 1.00 1.0000 .00000 14.00
[0103] 0.938 .79 .80 .7964 .00638 5.00 0.469 .73 .75 .7385 .00966 2.00
[0104] C.krusei 30 1.00 1.00 1.0000 .00000 14.00 19.837 .003*
[0105] ATCC 6258 15 1.00 1.00 1.0000 .00000 14.00
[0106] (3)
[0107] 7.5 1.00 1.00 1.0000 .00000 14.00
[0108] 3.75 1.00 1.00 1.0000 .00000 14.00
[0109] 1.875 1.00 1.00 1.0000 .00000 14.00
[0110] 0.938 .52 .55 .5368 .01419 2.00
[0111] 0.469 .66 .66 .6596 .00358 5.00
[0112] C. glabrata 30 1.00 1.00 1.0000 .00000 17.00 19.775 .003*
[0113] ATCC 2001 15 1.00 1.00 1.0000 .00000 17.00
[0114] (4)
[0115] 7.5 1.00 1.00 1.0000 .00000 17.00
[0116] 3.75 .47 .48 .4751 .00632 8.00
[0117] 1.875 .58 .60 .5896 .01225 11.00
[0118] 0.938 .23 .27 .2512 .02080 2.00
[0119] 0.469 .28 .30 .2861 .00937 5.00
[0120] *p<0.05
[0121] Evaluation between the combination of Candida strains and TQ-nystatin doses When the interaction of TQ and nystatin was examined in vitro by microdilution method, it was observed that these two substances showed synergistic antifungal effect at a concentration of 0.234 pg / mL in strains other than C. krusei and concentration thereof was 0.117 pg / mL. In C. krusei, a statistically significant difference was observed between the mean ranks of Candida strains and TQ-nystatin combination doses (p<0.05). Concentrations of 0.117 pg / mL and above of the combination of thymoquinone and nystatin suppressed the growth of Candida albicans, C. tropicalis and C. glabrata, while concentrations of 0.059 pg / mL and above significantly suppressed the growth of C. krusei (Table 3). In addition, dose-effect plots for thymoquinone+nystatin are shown in Figure 3. According to the FIC index value, TQ and nystatin were found to have a synergistic effect on all strains (Table 4).
[0122] Table 3: Comparison of combination TQ-nystatin doses in Candida species Dose _ Mean
[0123] Species Min Mak x SS2p
[0124] (pg / mL) ranks
[0125] C.albicans 15 1.00 1.00 1.0000 .00000 17.00 25.880 .001*
[0126] ATCC 7,5 1.00 1.00 1.0000 .00000 17.00
[0127] 10231 (1)
[0128] 3.75 1.00 1.00 1.0000 .00000 17.00
[0129] 1.875 1.00 1.00 1.0000 .00000 17.00
[0130] 0.938 1.00 1.00 1.0000 .00000 17.00
[0131] 0.469 1.00 1.00 1.0000 .00000 17.00
[0132] 0.234 1.00 1.00 1.0000 .00000 17.00
[0133] 0.117 .48 .49 .4874 .00549 5.00
[0134] 0.059 .18 .19 .1854 .00798 2.00
[0135] C.tropicalis 15 1.00 1.00 1.0000 .00000 17.00 25.880 .001*
[0136] ATCC 7.5 1.00 1.00 1.0000 .00000 17.00
[0137] 750(2)
[0138] 3.75 1.00 1.00 1.0000 .00000 17.00
[0139] 1.875 1.00 1.00 1.0000 .00000 17.00
[0140] 0.938 1.00 1.00 1.0000 .00000 17.00
[0141] 0.469 1.00 1.00 1.0000 .00000 17.00
[0142] 0.234 1.00 1.00 1.0000 .00000 17.00
[0143] 0.117 .51 .52 .5130 .00325 5.00
[0144] 0.059 .47 .48 .4770 .00507 2.00
[0145] C.krusei 15 1.00 1.00 1.0000 .00000 15.50 25.893 .001*
[0146] ATCC 6258 7.5 1.00 1.00 1.0000 .00000 15.50
[0147] (3)
[0148] 3.75 1.00 1.00 1.0000 .00000 15.50
[0149] 1.875 1.00 1.00 1.0000 .00000 15.50
[0150] 0.938 1.00 1.00 1.0000 .00000 15.50
[0151] 0.469 1.00 1.00 1.0000 .00000 15.50
[0152] 0.234 1.00 1.00 1.0000 .00000 15.50
[0153] 0.117 1.00 1.00 1.0000 .00000 15.50
[0154] 0.059 .82 .82 .8209 .00193 2.00 C.glabrata 15 1.00 1.00 1.0000 .00000 17.00 25.880 .001*
[0155] A TCC 2001
[0156] (4)
[0157] 7.5 1.00 1.00 1.0000 .00000 17.00
[0158] 3.75 1.00 1.00 1.0000 .00000 17.00
[0159] 1.875 1.00 1.00 1.0000 .00000 17.00
[0160] 0.938 1.00 1.00 1.0000 .00000 17.00
[0161] 0.469 1.00 1.00 1.0000 .00000 17.00
[0162] 0.234 1.00 1.00 1.0000 .00000 17.00
[0163] 0.117 .79 .80 .7963 .00707 5.00
[0164] 0.059 .69 .69 .6891 .00101 2.00
[0165] *p<0.05
[0166] Table 4: MIC values of thymoquinone and nystatin combination against Candida strains and their combined FIC index values
[0167] Thymoqui l 15 7.5 3.75 1.875 0.938 0.469 0.234 0.117 0.059 none C
[0168] +Nystatin
[0169] (fig / mL)
[0170] Calbicans 0.14 100.0 100.0 100.0 100.0 100.0 100.0 100.0 48.74 18.54
[0171] ATCC 1 0% 0% 0% 0% 0% 0% 0% % %
[0172] 10231 (1)
[0173] Ctropicalis 0.14 100.0 100.0 100.0 100.0 100.0 100.0 100.0 51.30 47.70
[0174] ATCC 750 1 0% 0% 0% 0% 0% 0% 0% % %
[0175] (2)
[0176] Ckrusei 0.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 82.09
[0177] ATCC 7 0% 0% 0% 0% 0% 0% 0% 0% %
[0178] 6258 (3)
[0179] Cglabrata 0.24 100.0 100.0 100.0 100.0 100.0 100.0 100.0 79.63 68.91
[0180] ATCC 2 0% 0% 0% 0% 0% 0% 0% % %
[0181] 2001 (4) The mouthwash form of nystatin is routinely used in the treatment of oral candidiasis. However, as seen in the study, it is necessary to increase the dose of use in persistent Candida strains. Thus, it causes dose-related toxicity. The combination of thymoquinone and nystatin (as shown in Figure 3) has shown therapeutic efficacy in all Candida strains at very small administration doses. Therefore, by formulating the composition of the invention into a drug form, the invention is a novelty to existing drugs that are ineffective or cause toxicity in persistent Candida species.
Claims
CLAIMS1- A method of manufacturing the formulation for use in the treatment of fungal (candidiasis) diseases of the oral cavity, characterized in that it includes the following process steps: the final concentrations of TQ and nystatin combination in Brain Heart Infusion Broth (BHI) are 30 pg / mL, 15 pg / mL, 7.5 pg / mL, 3.75 pg / mL, 1.875 pg / mL, 0.938 pg / mL, 0.469 pg / mL and 0.234 pg / mL for Candida albicans ATCC 10,231 (1), C. tropikalis ATCC 750 (2), C. krusei ATCC 6258 (3) and C.glabrata ATCC 2001 (4) strains. C. albicans ATCC 10,231 (1), C. tropicalis ATCC 750 (2), C. krusei ATCC 6258 (3) and C. glabrata ATCC 2001 (4) strains are diluted according to a 0.5 McFarland turbidity standard,10 pL is added to each well and incubated overnight at 37 °C. Fungal growth in each well is measured at 600 nm using a spectrophotometer according to the manufacturer's instructions, the values of thymoquinone, nystatin and Candida strains in the control wells and the values obtained from the combinations of TQ and nystatin are used to determine the fractional inhibitory concentration (FIC), these FIC values and the values of the FIC index are calculated and thymoquinone and nystatin are combined.2- A herbal composition in which thymoquinone and nystatin are mixed in certain proportions for the treatment of fungal diseases (candidiasis) in the oral cavity, characterized in that it contains 50% nystatin and 50% thymoquinone.
Citation Information
Patent Citations
Oral cavity gel for treating oral candidiasis
CN108324681A
Treatment of covid-19 lung injury using umbilical cord plasma based compositions
US20220395540A1
